Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High – What’s Next?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $46.99 and last traded at $44.78, with a volume of 461795 shares changing hands. The stock had previously closed at $44.92.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Royal Bank Of Canada lifted their target price on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Wolfe Research began coverage on shares of Xenon Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Wells Fargo & Company boosted their target price on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Buy” and an average target price of $55.17.

Xenon Pharmaceuticals Stock Down 3.5%

The firm has a 50 day moving average price of $42.51 and a 200 day moving average price of $40.94. The stock has a market capitalization of $3.35 billion, a PE ratio of -11.12 and a beta of 0.96.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the firm earned ($0.84) earnings per share. On average, equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the sale, the chief executive officer owned 6,000 shares in the company, valued at approximately $266,580. This trade represents a 86.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 65,205 shares of company stock worth $2,919,762 over the last ninety days. 4.07% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently bought and sold shares of XENE. Corient Private Wealth LLC bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at $1,125,000. Mackenzie Financial Corp bought a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $210,000. ADAR1 Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals by 7.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock worth $9,142,000 after buying an additional 14,871 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth $964,000. Finally, Virtus Investment Advisers LLC increased its position in shares of Xenon Pharmaceuticals by 74.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 2,568 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.